[{"id":"f774fc32-7fec-4060-8b77-b180f136ab25","acronym":"","url":"https://clinicaltrials.gov/study/NCT02444819","created_at":"2021-01-18T11:42:56.779Z","updated_at":"2024-07-02T16:37:11.254Z","phase":"Phase 2","brief_title":"Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy","source_id_and_acronym":"NCT02444819","lead_sponsor":"Hanmi Pharmaceutical Company Limited","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Olita (olmutinib)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 08/01/2017","primary_completion_date":" 08/01/2017","study_txt":" Completion: 08/01/2017","study_completion_date":" 08/01/2017","last_update_posted":"2018-04-24"}]